Table 1 Clinical characteristics of study subjects by Mt5178 C/A genotype

Age (years)^a

54.5 (7.6)

53.6 (7.8)

0.245

BMI (kg/m²)^a

23.1 (2.8)

23.5 (2.6)

0.103

SBP (mmHg)^b

126.1 (16.0)

125.3 (13.9)

0.614

DBP (mmHg)^b

73.9 (10.5)

73.5 (9.0)

0.628

AST (U/L)^c

22 (18–27)

23 (19–27)

0.687

ALT (U/L)^c

21 (15–32)

24 (18–35)

0.471

AST/ALT ratio^c

1.037 (0.818–1.286)

0.918 (0.723–1.190)

0.004

GGT (U/L)^c

42 (27–75)

47 (30–75)

0.427

TC (mg/dL)^a

204.2 (31.5)

202.5 (31.9)

0.590

LDL-C (mg/dL)^a

122.5 (30.4)

118.4 (31.7)

0.182

HDL-C (mg/dL)^b

55.1 (13.6)

55.9 (15.7)

0.576

TG (mg/dL)^c

112 (84–156)

113 (83–161)

0.378

Subjects with ≥140 mg/dL LDL-C (%)^d

25.5

27.1

0.721

Subjects with ≥150 mg/dL TG (%)^d

28.3

29.4

0.803

FPG (mg/dL)^c

97 (92–105)

97 (91–103)

0.240

UA (mg/dL)^a

5.93 (1.28)

5.98 (1.21)

0.686

Coffee consumption (<1 cup per day/1–2 cups per day/≥3 cups per day) (%)^d

45.8/31.5/22.7

36.5/40.0/23.5

0.120

Green tea consumption (≤1 cup per day/2–3 cups per day/≥4 cups per day) (%)^d

26.7/30.7/42.6

27.7/32.9/39.4

0.798

Alcohol consumption (non- or ex-/occasionally/daily drinkers) (%)^d

17.9/34.3/47.8

12.9/40.0/47.1

0.285

Current smokers (%)^d

58.6

58.2

0.946

Subjects under antihypertensive treatment (%)^d

19.9

13.5

0.089

Subjects under antidiabetic treatment (%)^d

7.2

7.7

0.855